Clinical trials: Obesity (BMI Equal to or >30), active
Obesity (BMI Equal to or >30), Immune Function
Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles
The purpose of this intervention study is to investigate the effects of daily egg intake on markers of gut health, high-density lipoprotein (HDL), metabolic, and immune cell profiles in adults with body mass indexes (BMI) in…
- Conditions
- Obesity (BMI Equal to or >30), Immune Function, HDL, Gut Microbiome
- Trial name
- NCT07844616
- Testing
- Egg whites, Whole eggs
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Obesity / Overweight, Obesity (BMI Equal to or >30)
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
This study is designed as a single-blind, placebo-controlled, randomized, parallel-group trial. Subjects will be randomized in a 2:1 ratio to receive either NKS-3 or matching placebo, with a total planned enrollment of 31…
- Trial name
- SERENITY-1 (NCT07882654)
- Testing
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120
- Where
- Tunisia
- Volunteers
- 31 people
- Sponsor
- EktaH
Obesity (BMI Equal to or >30), Postmenopausal Symptoms
Time-Restricted Eating and Personalized Energy-Restricted Diet in Obese Postmenopausal Women
This clinical study aims to compare the effects of time-restricted eating and a personalized energy-restricted diet on anthropometric measurements, body composition, biochemical parameters, blood pressure, handgrip strength…
- Conditions
- Obesity (BMI Equal to or >30), Postmenopausal Symptoms, Sleep Quality
- Trial name
- NCT07874399
- Testing
- Time-Restricted Eating, Personalized Energy-Restricted Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Gazi University
Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
- Trial name
- SEMA AUD (NCT07772960)
- Testing
- Semaglutide 1.0 mg, Semaglutide 2.0 mg
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Yale University